Tags

Type your tag names separated by a space and hit enter

Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances.
Expert Rev Neurother 2007; 7(9):1157-63ER

Abstract

Recent years have seen a dramatic increase in the number of clinical trials investigating the potential efficacy of medicinal cannabinoids for the symptomatic treatment of chronic pain and spasticity in multiple sclerosis (MS). A number of different cannabinoids have been used, including: delta9-tetrahydrocannabinol (THC) itself; the synthetic delta9-THC, dronabinol; a 1:1 ratio of delta9-THC:cannabidiol (Sativex); and the synthetic delta9-THC metabolites CT-3 and nabilone. Other Cannabis extracts have also been tested. While 2-3 years ago there was little consensus in the literature, now the majority of studies are beginning to suggest that cannabinoids are useful in the treatment of MS in at least a subset of individuals. Their adverse side-effect profile has generally been mild compared with other drugs used for pain and spasticity; nonetheless, there is still concern about potential long-term side effects, particularly psychiatric side effects and effects on fetal development.

Authors+Show Affiliations

University of Otago, Department of Pharmacology & Toxicology, School of Medical Sciences, Dunedin, New Zealand. paul.smith@stonebow.otago.ac.nz

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17868014

Citation

Smith, Paul F.. "Symptomatic Treatment of Multiple Sclerosis Using Cannabinoids: Recent Advances." Expert Review of Neurotherapeutics, vol. 7, no. 9, 2007, pp. 1157-63.
Smith PF. Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances. Expert Rev Neurother. 2007;7(9):1157-63.
Smith, P. F. (2007). Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances. Expert Review of Neurotherapeutics, 7(9), pp. 1157-63.
Smith PF. Symptomatic Treatment of Multiple Sclerosis Using Cannabinoids: Recent Advances. Expert Rev Neurother. 2007;7(9):1157-63. PubMed PMID: 17868014.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances. A1 - Smith,Paul F, PY - 2007/9/18/pubmed PY - 2007/10/19/medline PY - 2007/9/18/entrez SP - 1157 EP - 63 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 7 IS - 9 N2 - Recent years have seen a dramatic increase in the number of clinical trials investigating the potential efficacy of medicinal cannabinoids for the symptomatic treatment of chronic pain and spasticity in multiple sclerosis (MS). A number of different cannabinoids have been used, including: delta9-tetrahydrocannabinol (THC) itself; the synthetic delta9-THC, dronabinol; a 1:1 ratio of delta9-THC:cannabidiol (Sativex); and the synthetic delta9-THC metabolites CT-3 and nabilone. Other Cannabis extracts have also been tested. While 2-3 years ago there was little consensus in the literature, now the majority of studies are beginning to suggest that cannabinoids are useful in the treatment of MS in at least a subset of individuals. Their adverse side-effect profile has generally been mild compared with other drugs used for pain and spasticity; nonetheless, there is still concern about potential long-term side effects, particularly psychiatric side effects and effects on fetal development. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/17868014/Symptomatic_treatment_of_multiple_sclerosis_using_cannabinoids:_recent_advances_ L2 - http://www.tandfonline.com/doi/full/10.1586/14737175.7.9.1157 DB - PRIME DP - Unbound Medicine ER -